Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The addition of Tecentriq (atezolizumab) to chemoradiation remedy led to significant long-term enhancements in high quality of life, with related quality-adjusted survival...
The U.S. Meals and Drug Administration (FDA) has authorised two new biosimilars for denosumab-qbde: Enoby (denosumab-qbde) and Xtrenbo (denosumab-qbde), in response to...
